Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03430011 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT03430011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2018
Completion date
March 30, 2023
Enrollment
165 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma